Table 1 Characteristics of clinical trials included in the meta-analysis
From: The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Study (phase) | First author | Cancer type | Treatment arm (No. of patients) | Control arm 1 (No. of patients) | Control arm 2 (No. of patients) | Refs. |
|---|---|---|---|---|---|---|
Alliance A091401 Phase 2 | D’Angelo SP | Sarcoma | Nivolumab plus Ipilimumab (42) | Nivolumab (43) | [29] | |
CheckMate 032 Phase 1/2 | Janjigian YY | Esophagogastric Cancer | Nivolumab plus Ipilimumab (101) | Nivolumab (59) | [13] | |
CheckMate 067 Phase 3 | Hodi FS | Melanoma | Nivolumab plus Ipilimumab (314) | Nivolumab (316) | Ipilimumab (315) | [30] |
CheckMate 069 Phase 2 | Hodi FS | Melanoma | Nivolumab plus Ipilimumab (95) | Ipilimumab (47) | [31] | |
CheckMate 214 Phase 3 | Motzer RJ | Renal-Cell Carcinoma | Nivolumab plus Ipilimumab (550) | Sunitinib (546) | [32] | |
CheckMate 227a Phase 3 | Hellmann MD | NSCLC | Nivolumab plus Ipilimumab (583) | Nivolumab (396) | Chemotherapy (583) | [33] |
NCT02374242b Phase 2 | Long GV | Melanoma | Nivolumab plus Ipilimumab (35) | Nivolumab (31) | [34] | |
Checkmate 143c Phase 1 | Omuro A | Glioblastoma | Nivolumab plus Ipilimumab (10) | Nivolumab (10) | [35] |